Source:

Healio Interview

Disclosures: Markman reports a consultant role with Merck related to the company’s anti-cancer drug therapeutics.
January 25, 2022
1 min watch
Save

Despite benefits of catch-up series, HPV vaccination efforts must ‘remain on the young’

Source:

Healio Interview

Disclosures: Markman reports a consultant role with Merck related to the company’s anti-cancer drug therapeutics.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In the final installment of a four-video series timed to Cervical Cancer Awareness Month, Maurie Markman, MD, spoke with Healio about which adults may derive the most benefit from catch-up HPV vaccination.

Vaccination may protect some adults from persistent infection, according to Markman, president of medicine and science at Cancer Treatment Centers of America and a HemOnc Today Editorial Board member.

However, he emphasized the focus of HPV vaccination efforts must remain on younger individuals.

“Before sexual debut is when we have the greatest opportunity ... to completely protect an individual from developing a persistent HPV infection,” Markman told Healio.